Β-lactam antibiotic reactions to any β-lactam antibiotic may occur in up to 10% of patients receiving that agent (a small fraction of which are truly IgE-mediated allergic reactions, see amoxicillin rash). Anaphylaxis will occur in approximately 0.01% of patients. There is perhaps a 5%-10% cross-sensitivity between penicillin-derivatives, cephalosporins, and carbapenems; but this figure has been challenged by various investigators. Nevertheless, the risk of cross-reactivity is sufficient to warrant the contraindication of all β-lactam antibiotics in patients with a history of severe allergic reactions (urticaria, anaphylaxis, interstitial nephritis) to any β-lactam antibiotic. A Jarisch–Herxheimer reaction may occur after initial treatment of a spirochetal
Antibiotic Resistance Lab Network Antibiotic Resistance Lab Network The Antibiotic Resistance Lab Network (ARLN) is a group of laboratories of the United States Centers for Disease Control and Prevention established to supplement the work of local and state public health laboratories in the identification and research of antibiotic resistance. It was created as part of the CDC's "National Action Plan for Combating Antibiotic Resistant Bacteria". The network is part of the National Center for Emerging and Zoonotic Infectious Diseases. Laboratories in this network cover seven regions and are located in Maryland, Minnesota, New York, Tennessee, Texas, Washington, and Wisconsin, as part of their state